Translational Immunology Section

Photo of Translational Immunology Section banner

Massimo Gadina, Ph.D.
Chief, Translational Immunology Section
Chief, Office of Science and Technology
Building 10 Room 6D47A
Phone: (301) 443-5457
Fax: (301) 402-0012

Research Overview

The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting edge immune monitoring technology that will be made available to all NIAMS investigators.

Through the TIS, NIAMS researchers will be provided with services, consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient. The TIS boasts state-of-the-art immunoassays such as multicolor flow cytometry and Luminex, which will allow NIAMS clinicians to monitor the immune responses of their clinical trial patients. Analysis of a reference population to define baseline responses will allow for quality control checks that will validate the reproducibility of these results.

Selected Publications

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014 Mar 6;370(10):911-20. doi: 10.1056/NEJMoa1307361. Epub 2014 Feb 19. PubMed Icon

Furumoto Y, Gadina M. The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders. BioDrugs. 2013 Jun 7. [Epub ahead of print] PubMed Icon

Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep. 2012;4:5. Epub 2012 Mar 1. PubMed Icon

O'Shea JJ, Gadina M, Kanno Y. Cytokine signaling: birth of a pathway. J Immunol. 2011 Dec 1;187(11):5475-8. doi: 10.4049/jimmunol.1102913. PubMed Icon

Jesus AA, Osman M, Silva CA, Kim PW, Pham TH, Gadina M, Yang B, Bertola DR, Carneiro-Sampaio M, Ferguson PJ, Renshaw BR, Schooley K, Brown M, Al-Dosari A, Al-Alami J, Sims JE, Goldbach-Mansky R, El-Shanti H. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 2011 Dec;63(12):4007-17. doi: 10.1002/art.30588. PubMed Icon

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, Labranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. PubMed Icon

Yang B, Hang-Pham T, Goldbach-Mansky R, Gadina M. Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay.J Vis Exp. 2011 Mar 1;(49). pii: 2662. doi: 10.3791/2662. PubMed Icon

Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gl A. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behet's disease. Nat Genet. 2010 Aug;42(8):698-702. PubMed Icon

Gadina M, O'Shea JJ. Immune modulation: Turncoat regulatory T cells. Nat Med. 2009 Dec;15(12):1365. PubMed Icon

Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgrd U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009 Jun 4;360(23):2426-37. PubMed Icon

See extended list of publications


Reviewed September 24, 2012